Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMorgan Sindall Group Regulatory News (MGNS)

Share Price Information for Morgan Sindall Group (MGNS)

Share Price is delayed by 15 minutes
Get Live Data
4,788.00    -94.00 (-1.93%)
Bid:
4,780.00
Ask:
4,782.00
Spread: 2.00 (0.042%)
Market Cap: £2.23b
MGNS Live PriceLast checked at - London Stock Exchange

Intraday Morgan Sindall Group Share Chart

AGM Voting Update

4 Sep 2023 12:51

RNS Number : 3096L
Morgan Sindall Group PLC
04 September 2023
 

Morgan Sindall Group plc

Legal Entity Identifier (LEI) number: 2138008339ULDGZRB345

 

4 September 2023

Morgan Sindall Group plc ("the Company")

 

Update on response to 2023 AGM voting outcome

 

At our Annual General Meeting ('AGM') held on 4 May 2023, resolution 3 (Approval of the Directors' Remuneration Policy) was supported by a large majority of shareholders but received less than 80% support overall.

 

In advance of the 2023 AGM, the Remuneration Committee (the 'Committee') undertook a detailed engagement with the Company's largest shareholders in relation to the remuneration proposals, and had amended the final Remuneration Policy design in response to feedback received. Following the 2023 AGM, the Committee reached out to the Company's largest shareholders to continue the dialogue and listen to their views - and in particular to understand why those who either abstained or voted against the Directors' Remuneration Policy ('the 'Policy') had done so.

 

The Committee received responses from eight investors, the majority of whom reconfirmed support for the Policy and the management team. 

 

One shareholder raised the annual bonus deferral requirement and 2nd-year phasing down of the post-employment shareholding requirement as their reason for not supporting the resolution. In both cases the Committee is comfortable that its current approach supports appropriate alignment of executive and shareholder interests. In respect of the annual bonus deferral requirement, the Committee also considers this requirement appropriate given the current shareholdings of incumbent Executive Directors. However, the Committee will reconsider both of these Policy design features as part of the next Policy review.

 

The Committee also received feedback from two shareholders that their voting had reflected the 'against' recommendation from one of the major proxy voting agencies, which itself was primarily a result of the simultaneous increases to the Policy headroom available under the annual bonus and LTIP schemes. On this matter, the Committee maintains its view that the Policy should be sufficiently flexible to last for a full triennial review period rather than needing to revert to shareholders to seek incremental changes, and reiterates its commitment to write out to major shareholders in advance of using the increased maximum opportunities under either of the variable incentives.

 

Another shareholder requested that the Committee provide a full explanation in its Remuneration Report of the rationale for the adoption of any increase to the executive directors' incentive opportunities in future years, particularly in relation to the achievement of key strategic objectives, and this feedback is consistent with the current thinking of the Committee.

 

The Committee continues to be grateful for the feedback received and the two-way engagement with major shareholders. Given overall majority support was obtained for the Policy resolution, it is not proposed to make any further changes to the approach to remuneration that was set out in the 2022 Annual Report. The Company will, however, continue to keep the Policy under review over the coming years and welcomes ongoing dialogue with shareholders and proxy advisers.

 

 

Enquiries:

Clare Sheridan, Company Secretary +44 (0) 20 7307 9200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFZLFBXKLEBBF
Date   Source Headline
15th Mar 20133:39 pmRNSHolding(s) in Company
13th Mar 20135:18 pmRNSHolding(s) in Company
1st Mar 201311:17 amRNSHolding(s) in Company
28th Feb 20133:59 pmRNSTotal Voting Rights
27th Feb 20135:21 pmRNSDirector/PDMR Shareholding
27th Feb 20132:56 pmRNSDirector/PDMR Shareholding
25th Feb 20137:00 amRNSBoard Changes
19th Feb 20137:00 amRNSPreliminary Results
8th Feb 201312:54 pmRNSHolding(s) in Company
8th Feb 201312:52 pmRNSHolding(s) in Company
31st Jan 20135:01 pmRNSTotal Voting Rights
10th Jan 20137:00 amRNSAppointment of Steve Crummett as Finance Director
31st Dec 20128:00 amRNSTotal Voting Rights
18th Dec 20127:00 amRNSPre-Close Statement
11th Dec 20124:43 pmRNSBlocklisting Interim Review
10th Dec 20122:22 pmRNSTotal Voting Rights
10th Dec 201211:26 amRNSAdditional Listing
22nd Nov 20127:00 amRNSMorgan Sindall increases investment in ISIS
20th Nov 20127:00 amRNSAWARD OF INFRASTRUCTURE PROJECTS TOTALLING £42M
19th Nov 20124:06 pmRNSDirector/PDMR Shareholding
6th Nov 20127:00 amRNSBoard Changes
6th Nov 20127:00 amRNSInterim Management Statement
31st Oct 201211:20 amRNSTotal Voting Rights
12th Oct 20129:07 amRNSPreferred partner - £1.1bn Sellafield Ltd contract
2nd Oct 20121:41 pmRNSTotal Voting Rights
20th Sep 201210:45 amRNSPreferred partner for £1 bn regeneration scheme
6th Aug 20127:00 amRNSHalf Yearly Report
31st Jul 201212:56 pmRNSTotal Voting Rights
24th Jul 20122:46 pmRNSHolding(s) in Company
23rd Jul 20127:00 amRNSMorgan Sindall sells medical property investments
3rd Jul 20127:00 amRNSAnalyst Site Visit
28th Jun 20127:00 amRNSPRE-CLOSE TRADING UPDATE
22nd May 20128:10 amRNSDirector/PDMR Shareholding
16th May 20129:00 amRNS£50m repairs contract with Accord Group
3rd May 20124:04 pmRNSAGM Statement
3rd May 20127:00 amRNSAGM and Interim Management Statement
30th Mar 201210:27 amRNSDirector/PDMR Shareholding
27th Mar 201210:32 amRNSAnnual Financial Report
27th Mar 201210:00 amRNSMorgan Sindall Group appointed preferred developer
23rd Mar 20123:12 pmRNSAnnual Information Update
1st Mar 20125:26 pmRNSDirector/PDMR Shareholding
29th Feb 20122:55 pmRNSTotal Voting Rights
21st Feb 20127:00 amRNSFinal Results
16th Feb 20127:00 amRNSSale of interest in the Dorset Fire & Rescue PFI
10th Feb 201210:14 amRNSAdditional Listing
6th Feb 201211:00 amRNSAwarded five-year substation contract extension
1st Feb 20124:02 pmRNSHolding(s) in Company
31st Jan 20127:00 amRNSMorgan Sindall Awarded New Energy Scheme
25th Jan 20127:00 amRNSAppointment of Joint Corporate Broker
23rd Jan 20127:01 amRNSSelected as Partner for Infrastructure Programme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.